Press releases

These press releases are intended for business journalists and analysts/investors

Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

•150 healthy adult and elderly participants expected to be enrolled in Phase 1 study
•COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results
•Preliminary safety and immunogenicity results expected in August 2020
•Global Phase 2b/3 vaccine efficacy study is in planning stage, targeting initiation by year-end 2020

Read more - Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate Read more

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

•Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition
•Participants who were in the daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (FTC/TDF) tablet arm of the study will be offered CAB LA

Read more - Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP Read more